[Value of electroretinography in the objective evaluation of tissue circulation therapy].
D000840:Anisoles / Q000009:adverse effects / Q000627:therapeutic use; D002396:Catechols / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D004596:Electroretinography; D000431:Ethanol / Q000009:adverse effects / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D007511:Ischemia / Q000188:drug therapy; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D012162:Retinal Degeneration / Q000188:drug therapy; D012164:Retinal Diseases / Q000188:drug therapy*; D012171:Retinal Vessels / Q000187:drug effects*; D015016:Yohimbine / Q000009:adverse effects / Q000627:therapeutic use
D000840:Anisoles; D002396:Catechols; D004338:Drug Combinations; D010879:Piperazines; D015016:Yohimbine; D000431:Ethanol
Place de l'électrorétinographie dans l'appréciation objective d'une hérapeutique circulatoire tissulaire.